Literature DB >> 21455396

Cardiovascular response to ect is unaffected by extent of motor seizure modification.

N Murali1, E S Saravanan, M G Santosh, B N Gangadhar, N Janakiramaiah, G S Rao, S S Kumar, D K Subbakrishna, R Christopher.   

Abstract

Effect of the extent of motor seizure modification on cardiovascular responses in ECT was studied at the second ECT session in 50 (ULECT=25) consenting patients. Twenty five patients each received either 0.5 mg/kg or 1 mg/kg of succinylcholine in a random design. Blood pressure and heart rate were recorded on five occasions during the ECT session. Extent of motor seizure was assessed on a five point scale by two raters blind to succinylcholine dose. Two raters had good interrater agreement on the scale. Significantly more patients had poor modification with 0.5 mg/kg (68%) than with 1 mg/kg (12%) of succinylcholine. Rate-pressure-product (RPP=systolic BPx Heart rate) significantly changed over the five occasions, maximal being in ictal occasion, but the two succinylcholine dose groups did not differ. Ictal RPP positively correlated with post-anaesthesia RPP, ECT stimulus dose, seizure threshold and both seizure durations (Motor and EEG). Likewise, postictal RPP correlated with seizure threshold and actual ECT stimulus dose. Neither correlated with the motor seizure modification scores. In multiple, stepwise, linear regression models neither ictal nor post-ictal RPP variance was significantly explained by the extent of motor seizure modification scores. Hence, RPP changes during ECT may be reflecting cerebral mechanisms of ECT.

Entities:  

Keywords:  ECT; Rate pressure product; motor seizure modification; succinylcholine dose

Year:  1999        PMID: 21455396      PMCID: PMC2962998     

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


  7 in total

1.  Age-Related Changes in Cardiovascular Function Associated with Electroconvulsive Therapy.

Authors:  Kou Chu Huang; Linda F. Lucas; Kentaro Tsueda; Mary H. Thomas; Steven B. Lippmann
Journal:  Convuls Ther       Date:  1989

2.  Cardiovascular response to unilateral electroconvulsive therapy.

Authors:  M C Webb; C E Coffey; W R Saunders; M M Cress; R D Weiner; T R Sibert
Journal:  Biol Psychiatry       Date:  1990-11-01       Impact factor: 13.382

3.  Atropine premedication and the cardiovascular response to electroconvulsive therapy.

Authors:  P M Mayur; R S Shree; B N Gangadhar; D K Subbakrishna; N Janakiramaiah; G S Rao
Journal:  Br J Anaesth       Date:  1998-09       Impact factor: 9.166

4.  Acute post-ECT cardiovascular response: a comparison of threshold right unilateral and bilateral ECT.

Authors:  P M Mayur; B N Gangadhar; K Girish; K M Prasad; D K Subbakrishna; N Janakiramiah
Journal:  J ECT       Date:  1998-06       Impact factor: 3.635

5.  Noninvasive assessment of electroconvulsive-induced changes in cardiac function.

Authors:  G D Mulgaokar; P J Dauchot; J P Duffy; A H Anton
Journal:  J Clin Psychiatry       Date:  1985-11       Impact factor: 4.384

6.  Cardiovascular and hormonal responses to electroconvulsive therapy. Modification of an exaggerated response in an hypertensive patient by beta-receptor blockade.

Authors:  R M Jones; P R Knight
Journal:  Anaesthesia       Date:  1981-08       Impact factor: 6.955

7.  Acute effects of ECT on cardiovascular functioning: relations to patient and treatment variables.

Authors:  J Prudic; H A Sackeim; P Decina; N Hopkins; F R Ross; S Malitz
Journal:  Acta Psychiatr Scand       Date:  1987-04       Impact factor: 6.392

  7 in total
  2 in total

1.  Ictal rpp - a supplement to cuff method in detecting ect-induced cerebral seizure.

Authors:  Neeraj Singh Gill; K Girish; B N Gangadhar
Journal:  Indian J Psychiatry       Date:  2002-01       Impact factor: 1.759

2.  Research on electroconvulsive therapy in India: An overview.

Authors:  Bangalore N Gangadhar; Vivek H Phutane; Jagadisha Thirthalli
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.